莎普爱思: 莎普爱思关于全资子公司获得盐酸毛果芸香碱滴眼液临床试验批准通知书的公告

Group 1 - The company Zhejiang Shapuaisi Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has received the clinical trial approval notice for Pilocarpine Hydrochloride Eye Drops from the National Medical Products Administration [1] - The drug is classified as a Class 3 chemical drug and is intended for the treatment of presbyopia in adults [1] - The total research and development investment for the Pilocarpine Hydrochloride Eye Drops project has reached approximately 6.4457 million RMB [1]